Exhibit
31.2
CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER
PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I,
Michael A. Kramarz, certify that:
(1) | | I
have reviewed this Quarterly Report on Form 10-Q of Oncologix Tech, Inc.; |
(2) | | Based
on my knowledge, the Report does not contain any untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements made, in light
of the circumstances under which such statements were made, not misleading with respect
to the period covered by the Report; |
(3) | | Based
on my knowledge, the financial statements, and other financial information included in
the Report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods represented
in this report; |
(4) | | The
registrant’s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(c) | | such
disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others
with these entities, particularly during the period in which this Report is being prepared; |
(d) | | Designed
such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
(c) | | Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented
in Report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this Report based on such evaluation; and |
(d) | | Disclosed
in this Report any change in the registrant’s internal control over financial reporting
that occurred during the registrant’s most recent fiscal quarter (the registrant’s
fourth fiscal quarter in case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over
financial reporting. |
(6) | | The
registrant’s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of the Registrant’s board of directors (or persons performing
the equivalent functions): |
(a) | | All
significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the
registrant’s ability to record, process, summarize and report financial information;
and |
(b) | | Any
fraud, whether or not material, that involves management or other employees who have
a significant role in the registrant’s internal control over financial reporting. |
Date: March 31, 2014 |
ONCOLOGIX TECH, INC. |
|
By |
/s/
Michael A. Kramarz |
|
|
Name:
Michael A. Kramarz
Title: Chief Financial Officer |